Get started

Bostonscientific

Boston Beer Reportedly in Sale Talks to SuntoryAccording to Wall Street, which cited anonymous sources, Boston Beer saw a spike in value on Friday, as the American brewer is in discussions to sell the business to the international spirits major Suntory. On the announcement, Boston Beer Company Inc. (NYSE:SAM) had a gain of almost 30%. The sources told WSJ that although negotiations are still in their early stages, there is no guarantee that a deal would be reached and that a rival bidder may emerge. Though demand has been hurt by shifting customer preferences, Boston Beer has had a difficult year thus far. This has given rise to rumors of a sale. After collaborating with Boston Beer to create new spirits and ready-to-drink drinks in 2021, Suntory is well-acquainted with the latter. Technical Outlook Boston Beer stock ( NYSE:SAM ) closed Fridays trading session up 22.33% with a Relative Strength Index (RSI) of 68.64 which is slightly overbought. The daily price chart pattern showed a "Bullish Harami" pattern which is a strong bullish reversal pattern.
NYSE:SAMLong
by DEXWireNews
🏥💼 Boston Scientific (BSX) Investment Analysis 💡📈Strategic Acquisitions: Boston Scientific's recent acquisitions, including Axonics, Relievant Medsystems, and partial offer for Acotec, signify its proactive expansion strategy, targeting new growth opportunities in medical segments and lucrative markets like China. Innovative Product Introductions: Introduction of innovative products strengthens Boston Scientific's industry position and demonstrates commitment to addressing unmet medical needs. Investment Outlook: Bullish sentiment on NYSE:BSX , fueled by strategic initiatives and potential for revenue growth. Upside target of $86.00-$88.00 reflects optimistic expectations for Boston Scientific's execution of growth strategies and capitalization on recent acquisitions and product launches. 📊🚀 Stay tuned for BSX's growth trajectory! #BostonScientific #InvestmentAnalysis 📈💼
NYSE:BSXLong
by Richtv_official
Boston Scientific To Acquire Axonics For About $3.7 Bln In a groundbreaking move, Boston Scientific Corporation (NYSE: BSX) has recently announced its definitive agreement to acquire Axonics, Inc. (Nasdaq: NASDAQ:AXNX ), a pioneering medical technology company specializing in the development and commercialization of advanced devices to address urinary and bowel dysfunction. This strategic acquisition, valued at approximately $3.7 billion, positions Boston Scientific at the forefront of the rapidly growing sacral neuromodulation (SNM) therapy market, offering innovative solutions for patients suffering from overactive bladder (OAB) and fecal incontinence. Axonics' Cutting-Edge Technology: Axonics has made significant strides in the field of urology with its state-of-the-art Axonics R20TM and Axonics F15TM Systems. These systems, which utilize sacral neuromodulation therapy, have demonstrated meaningful improvement in patients' quality of life over a two-year period, with no serious device-related adverse events reported. The recent FDA approval for the fourth-generation Axonics R20 neurostimulator, a rechargeable SNM device with an impressive battery life of 20 years or more, further solidifies Axonics' position as a leader in the market. Addressing a Growing Need: The acquisition comes at a crucial time when an estimated 30 million adults in the United States aged 40 and older experience bothersome symptoms of overactive bladder, and 19 million adults suffer from fecal incontinence. These conditions significantly impact patients' quality of life, mental health, sleep, productivity, and social activities. Boston Scientific's move to integrate Axonics' portfolio into its offerings reflects a commitment to addressing these often-chronic conditions with cutting-edge solutions. Strategic Implications for Boston Scientific: Meghan Scanlon, Senior Vice President and President, Urology at Boston Scientific, expressed excitement about the acquisition, emphasizing the potential to strengthen the company's ability to serve urologists and expand access to care for patients. The entry into sacral neuromodulation represents a high-growth adjacency for Boston Scientific, with opportunities for further innovation and market expansion. Financial Outlook and Impact: Axonics is expected to deliver net revenue of approximately $366 million in 2023, marking a remarkable 34% growth over the prior fiscal year. Boston Scientific anticipates the transaction to be completed in the first half of 2024, subject to customary closing conditions. While the impact on Boston Scientific's adjusted earnings per share is expected to be immaterial in 2024, the acquisition is projected to be accretive thereafter, reflecting the long-term value and growth potential of Axonics' revenue profile. Conclusion: Boston Scientific's acquisition of Axonics marks a significant milestone in the medical technology landscape, with the potential to revolutionize the treatment of urinary and bowel dysfunction. As the companies join forces, the collaboration is poised to bring about innovative solutions, ultimately improving the lives of millions of individuals grappling with these challenging health conditions. The move underscores Boston Scientific's commitment to advancing healthcare through strategic partnerships and cutting-edge technologies.
NASDAQ:AXNX
by DEXWireNews
1
$BSX Soars to Record Highs: A Compelling Investment Opportunity With a recent surge to record highs, fueled by positive developments and robust financial performance, here's a compelling case for potential buyers to consider adding NYSE:BSX stock to their portfolios. 1. Technical Analysis: Riding the Rising Trend Channel Boston Scientific is currently riding a rising trend channel in the medium to long term, reflecting increasing optimism among investors. The stock has recently broken a rectangle formation, further indicating a strong bullish sentiment. The absence of resistance in the price chart suggests the potential for continued upward momentum. A decisive break of the resistance at $56.91 is anticipated to trigger a further rise to $58.50 or more. 2. Strategic Gap-Up and Buy Zone Expansion The recent gap-up in Boston Scientific's stock price on heavy volume, coupled with bypassing a key alternative buy point at $56.90, underscores strong positive momentum. Investors should take note that shares are currently within a 5% buy zone, extending up to $59.75. This presents an attractive entry point for those looking to capitalize on the stock's upward trajectory. 3. FARAPULSE Treatment Anticipation Boosts Confidence Boston Scientific's recent announcement regarding the anticipated FDA approval of its FARAPULSE treatment for a heart condition in the first quarter of 2024 has significantly boosted investor confidence. This development not only signals the company's commitment to innovation but also opens up new revenue streams, potentially driving the stock price higher. 4. Impressive Year-to-Date Performance With a remarkable 24% gain in the current year, Boston Scientific has consistently outperformed market expectations. The stock touched a record high on a recent Friday, showcasing the market's positive response to the company's strategic initiatives and strong financial performance. 6. Upgraded 2023 Earnings Outlook Notably, Boston Scientific raised its full-year 2023 earnings outlook in its latest report, reflecting management's confidence in sustained growth. Such positive guidance provides investors with a clear signal of the company's strong fundamentals and future potential. As Boston Scientific continues its upward trajectory, propelled by a confluence of positive technical indicators, strategic developments, and robust financial performance, now may be an opportune moment for investors to consider adding NYSE:BSX stock to their portfolios. The anticipation of FDA approval for FARAPULSE, coupled with the company's impressive year-to-date gains, positions Boston Scientific as a compelling investment opportunity with the potential for continued growth in the foreseeable future. As always, investors are encouraged to conduct thorough research and consult with financial advisors before making any investment decisions.
NYSE:BSX
by DEXWireNews